IRVINE, Calif., April 3, 2008 (PRIME NEWSWIRE) -- Vitreoretinal Technologies, Inc. (VRT) today announced the enrollment of the first patients in a multinational Phase III clinical trial for evaluation of the safety and efficacy of VRT's investigational drug Vitreosolve(r) for diabetic retinopathy patients. The first patients were enrolled and treated at clinical sites both in the U.S. and India.
